Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac in cancer patients
NCT05313074Completed
- Sponsor
- National Cancer Institute of Thailand
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Cancer Institute of Thailand. Primary endpoint: Neutralizing antibody titers. Started Mar 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05313074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313074.